Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

2 Dividend Stocks to Buy and Never Sell


There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their non-dividend-paying peers in delivering strong market returns over long periods.

However, just because a company pays a dividend doesn't make it attractive in and of itself. Income seekers want stocks that can perform well and consistently raise their payouts over the long run. Although few have what it takes, two excellent candidates in this regard are Johnson Johnson (NYSE: JNJ) and (NYSE: MRK).

Johnson Johnson has faced several issues in recent years. First, revenue growth hasn't been as impressive as the market would have liked. Second, the company is still facing thousands of lawsuits related to its talc-based products, but multiple judges have shot down its attempts at a settlement. Third, recent regulatory changes in the U.S. have enabled Medicare to negotiate lower prices for some of the drugs it spends the most on, and the first round of negotiations will feature three of J's medicines.

Continue reading


Source Fool.com

Merck KGaA Aktie

112,80 €
2,22 %
Ein mittlerer Kursanstieg bei Merck KGaA heute, um 2,22 %.
Eine klare Neigung zu Buy-Einschätzungen bei Merck KGaA, ohne Sell-Einschätzungen.
Bei einem Kursziel von 185 € für Merck KGaA deutet sich eine Steigerung von über 50% vom aktuellen Kurs von 112.8 € an.
Like: 0
JNJ
Teilen

Kommentare